Status:
COMPLETED
Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer
Lead Sponsor:
Beth Israel Deaconess Medical Center
Conditions:
Breast Cancer
Eligibility:
All Genders
21+ years
Phase:
PHASE1
Brief Summary
Sentinel lymph node (SLN) mapping is the standard of care for the surgical staging of breast cancer. We propose a method of SLN mapping based on the use of invisible near-infrared fluorescent light th...
Detailed Description
The standard of care in breast cancer surgery includes identification and assessment of the sentinel lymph node (SLN). At the present time, SLN mapping utilizes a gamma ray-emitting radiotracer and/or...
Eligibility Criteria
Inclusion
- Women or men above the age of 21 who have biopsy-proven breast cancer, and who are undergoing sentinel lymph node mapping for staging and treatment of their disease.
Exclusion
- Pregnant women,
- Significant renal, cardiac, or pulmonary disease,
- History of iodine allergy.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00721370
Start Date
July 1 2008
End Date
January 1 2011
Last Update
February 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215